Logo

Sanofi and Kaken to Terminate their Co-Marketing Agreement for Clexane by the Year End 2019

Share this

Sanofi and Kaken to Terminate their Co-Marketing Agreement for Clexane by the Year End 2019

Shots:

  • In accordance with the expiration of the effective period of the co-marketing agreement- the companies will terminate their co-marketing agreement for Clexane SC Kit 2000 IU on Dec 31- 2019
  • In Jan’2008- Sanofi got manufacturing and marketing approval for Clexane SC Kit 2000 IU while Kaken initiated marketing and information service activities in Jul’2010 under the co-marketing agreement between the two companies
  • Clexane is an anticoagulant therapy indicated to prevent venous thromboembolism. From Jan 01- 2020 Sanofi will start marketing and information service activities for Clexane on its own

Click here to­ read full press release/ article | Ref: Kaken | Image: Amcham


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions